Strategic Insights Genes & Liens After the Gene RushPatently More DifficultNavigating Gene Patent MinefieldsAre Gene Patents in the Public Interest?News·Analysis Who’s Alpha Now? IBM In, HP OutWanted: The $1,000 GenomeTidying Up the Microarray Data MessGiving XML Special TreatmentSearch for FDA Leader EndsNow Screening: Dust-BustersChipping Away at AIDS MysteryClinical Data Standards Face Uphill BattleUnited Offers On-Demand GridCelera, LabCorp Join in Creating Improved Diagnostic TestsHumans Fall Further from Family TreeGenomics According to HaseltinePioneering Pharmacogenomics StandardsHorizonsJohn Craig Venter UnvarnishedCONVERSATION The former Celera CEO talks about that company's politics, the future of sequencing technology, and his own genome.A Collision of ContinentsGUEST COMMENTARY Biology and technology have evolved and merged to create the brave new world of "biotronics."The Business of BioinformaticsGUEST COMMENTARY The industry has reached an interesting crossroads.Columns & DepartmentsFirst Base | Kevin Davies Adventures at the Cannes Finance FestivalBusiness Watch | Debra Goldfarb · IDCDisruption — The Real Revolution Paper View | Kevin DaviesDNA for Dummies? New ProductsInforMax Enhances Analytical Tools · ABI Lets ICAT out of Bag · Biocluster in a BoxThe Dodge Retort | John Dodge Integration for the Masses
For reprints and/or copyright permission, please contact Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.